" class="no-js "lang="en-US"> Oxford/AstraZeneca Alternative Now Available at Riverside Vaccination Centre - Medtech Alert
Saturday, April 20, 2024

Oxford/AstraZeneca Alternative Now Available at Riverside Vaccination Centre

Vaccination appointments are available for residents who are eligible at the Riverside Vaccination Centre in Newport on the Isle of Wight, including those who are aged 30 years and over.

Vaccinations continue to be offered in line with recommendations from the independent JCVI.

If you’re under 40, you’ll be offered a Pfizer appointment as the alternative vaccine to Oxford/AstraZeneca.

If you’re 40 or over, you’ll be asked if you’re pregnant to make sure you’re only shown appointments for the right vaccine for you.

Do not leave Island for jab

Eligible people should book online or call 119. If residents attempt to book online but appointments slots are full, they should continue to keep checking the national booking system as more appointments will become available.

People do not have to travel to the mainland for a vaccination appointment unless they choose to do so.

The Riverside Centre in Newport is open seven days a week, 8am to 8pm and people can choose an appointment slot best suited to them.

Pfizer for Pfizer cohorts 1-9

Continues to be offered to cohorts 1-9 by the Primary Care Networks.

If you receive an invite from your GP, please do act on it as soon as possible so that you can join the millions of people who are helping to protect themselves and others. 

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more